133 related articles for article (PubMed ID: 28665228)
1. Absorption, metabolism and excretion of [
Xu S; Tatosian D; Mcintosh I; Caceres M; Matthews C; Samuel K; Selverian D; Kumar S; Kauh E
Xenobiotica; 2018 Jun; 48(6):584-591. PubMed ID: 28665228
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
Krishna R; Addy C; Tatosian D; Glasgow XS; Gendrano Iii IN; Robberechts M; Haazen W; de Hoon JN; Depré M; Martucci A; Peng JZ; Johnson-Levonas AO; Wagner JA; Stoch SA
J Clin Pharmacol; 2016 Dec; 56(12):1528-1537. PubMed ID: 27225334
[TBL] [Abstract][Full Text] [Related]
3. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Tsuchiya S; Friedman E; Addy C; Wakana A; Tatosian D; Matsumoto Y; Suzuki H; Kauh E
J Diabetes Investig; 2017 Jan; 8(1):84-92. PubMed ID: 27182005
[TBL] [Abstract][Full Text] [Related]
4. A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval.
Tatosian DA; Cardillo Marricco N; Glasgow XS; DeGroot B; Dunnington K; George L; Gendrano IN; Johnson-Levonas AO; Swearingen D; Kauh E
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):383-92. PubMed ID: 27627194
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological action and clinical results of Omarigliptin (MARIZEV
Ito Y; Mori M; Matsumoto Y; Okamoto T
Nihon Yakurigaku Zasshi; 2017; 149(3):128-137. PubMed ID: 28260743
[No Abstract] [Full Text] [Related]
7. Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.
Addy C; Tatosian DA; Glasgow XS; Gendrano IN; Sisk CM; Kauh EA; Stoch SA; Wagner JA
Clin Pharmacol Drug Dev; 2016 Sep; 5(5):374-82. PubMed ID: 27627193
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
[TBL] [Abstract][Full Text] [Related]
9. Omarigliptin: first global approval.
Burness CB
Drugs; 2015 Nov; 75(16):1947-52. PubMed ID: 26507988
[TBL] [Abstract][Full Text] [Related]
10. Omarigliptin for the treatment of type 2 diabetes.
Tan X
Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Gantz I; Chen M; Suryawanshi S; Ntabadde C; Shah S; O'Neill EA; Engel SS; Kaufman KD; Lai E
Cardiovasc Diabetol; 2017 Sep; 16(1):112. PubMed ID: 28893244
[TBL] [Abstract][Full Text] [Related]
12. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.
Biftu T; Sinha-Roy R; Chen P; Qian X; Feng D; Kuethe JT; Scapin G; Gao YD; Yan Y; Krueger D; Bak A; Eiermann G; He J; Cox J; Hicks J; Lyons K; He H; Salituro G; Tong S; Patel S; Doss G; Petrov A; Wu J; Xu SS; Sewall C; Zhang X; Zhang B; Thornberry NA; Weber AE
J Med Chem; 2014 Apr; 57(8):3205-12. PubMed ID: 24660890
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Wang X; Li X; Qie S; Zheng Y; Liu Y; Liu G
Medicine (Baltimore); 2018 Aug; 97(34):e11946. PubMed ID: 30142816
[TBL] [Abstract][Full Text] [Related]
14. Omarigliptin for the treatment of type 2 diabetes mellitus.
Evans PM; Bain SC
Expert Opin Pharmacother; 2016 Oct; 17(14):1947-52. PubMed ID: 27466703
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity-relationship of amide and sulfonamide analogs of omarigliptin.
Chen P; Feng D; Qian X; Apgar J; Wilkening R; Kuethe JT; Gao YD; Scapin G; Cox J; Doss G; Eiermann G; He H; Li X; Lyons KA; Metzger J; Petrov A; Wu JK; Xu S; Weber AE; Yan Y; Roy RS; Biftu T
Bioorg Med Chem Lett; 2015 Dec; 25(24):5767-71. PubMed ID: 26546218
[TBL] [Abstract][Full Text] [Related]
16. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
17. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
Ohara M; Nagaike H; Fujikawa T; Kohata Y; Ogawa M; Omachi T; Sasajima R; Chiba H; Ara T; Sugawara A; Hiromura M; Terasaki M; Mori Y; Fukui T; Hirano T; Yokoyama H; Yamagishi SI
Diabetes Res Clin Pract; 2021 Sep; 179():108999. PubMed ID: 34390762
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
19. Ultra-high pressure liquid chromatography-tandem mass spectrometry method for the determination of omarigliptin in rat plasma and its application to a pharmacokinetic study in rats.
Li MF; Hu XX; Ma AQ
Biomed Chromatogr; 2017 Oct; 31(10):. PubMed ID: 28317144
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans.
Furuta S; Smart C; Hackett A; Benning R; Warrington S
Xenobiotica; 2013 May; 43(5):432-42. PubMed ID: 23075005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
